Following the presentation of two abstracts at the Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA, the Pharming Group N.V. COO Bruno Giannetti (MD, PhD) said:
“This real-world evidence demonstrates that Ruconest continues to serve an important role in the management of HAE despite the availability of other therapeutic options.”
The presentations are:
- Impact of Hereditary Angioedema Prophylaxis With Recombinant Human C1 Esterase Inhibitor on Burden of Emergency Department Visits by Dr Douglas Jones, Rocky Mountain Allergy, Asthma and Immunology:
The authors report a patient on plasma-derived C1-INH prophylaxis who was still experiencing HAE attacks and required numerous visits to the emergency department (ED). The patient was switched to Ruconest prophylaxis, and the number of attacks requiring acute treatment decreased significantly (1 attack over a 15 month period) along with visits to the ED. - Recombinant Human C1 Esterase Inhibitor as Routine Short-Term Prophylaxis for Hereditary Angioedema Inadequately Controlled With Long-Term Prophylaxis During Menses by Dr Andrew Smith, Allergy Associates of Utah:
The authors report a patient suboptimally controlled with plasma-derived C1-INH prophylaxis, initially delivered intravenously and then switched to the subcutaneous route of administration. Because of frequent breakthrough attacks especially during menses, Ruconest was added to her regimen as a short-term prophylactic therapy. This resulted in a substantial reduction of her HAE symptoms, and the patient did not require any acute therapy since beginning Ruconest.
(Source: Pharming)
